T1	Participants 137 155	overactive bladder
T2	Participants 253 291	patients with overactive bladder (OAB)
T3	Participants 392 548	patients with continuous OAB symptoms for ≥ 3 months, daily mean voiding frequency (DMVF) ≥ 8, and daily mean urgency or urgency incontinence frequency ≥ 2.
